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Reducing the Flexibility of Type II Dehydroquinase Enzyme for 
Inhibition – A Fragment-Based Approach and Molecular 
Dynamics Simulation Study 
Antonio Peón,[a] Adrián Robles,[a]  Beatriz Blanco,[a] Marino Convertino,[b,δ] Paul Thompson,[c] Alastair R. 
Hawkins,[c] Amedeo Caflisch,*[b] and Concepción González-Bello*[a] 
 
Abstract: A multidisciplinary approach was used to identify and 
optimize a quinazolinedione-based ligand that would reduce the 
flexibility of the substrate-covering loop (catalytic loop) of the type II 
dehydroquinase from Helicobacter pylori. This enzyme, which is 
essential for the survival of this bacterium, is involved in the 
biosynthesis of the aromatic amino acids. A computer-aided 
fragment-based protocol (ALTA) was first employed to identify the 
aromatic fragments able to block the interface pocket that separates 
two neighbor enzyme subunits and is located at the active site 
entrance. Chemical modification of its non-aromatic moiety through 
an olefin cross metathesis and Seebach´s self-reproduction of 
chirality synthetic principle allowed the development of a 
quinazolinedione derivative that disables the catalytic loop plasticity, 
which is essential for the enzyme catalytic cycle. Molecular 
dynamics simulation studies revealed that the ligand would force the 
catalytic loop into an inappropriate arrangement for catalysis by 
strong interactions with the catalytic tyrosine and by expelling the 
essential arginine out of the active site. 
Introduction 
Although antibiotics are one of the most successful drugs in 
clinic that have saved millions of lives, many of them are 
nowadays ineffective in treating infections caused by resistant 
bacteria.1 This is a dramatic problem in people with a weak 
immune system or undergoing surgery, cancer chemotherapy, 
dialysis, etc. for which the treatment of secondary processes are 
crucial. One of the factors responsible for the actual resistant 
levels is the fact that most of the antibiotics in clinical use target 
a reduced and the same type of bacterial targets and resistance 
to them are well known and spread worldwide. To this end, in 
recent years much research has been devoted to the 
identification of new and unexploited therapeutic targets involved 
in key processes for bacterial survival as well as the detailed 
insight of the basis of their behavior and the identification of 
compounds targeting them.  
One of these interesting targets is the type II dehydroquinase (3-
dehydroquinate dehydratase, DHQ2, EC 4.2.1.10) that is the 
third enzyme of the shikimic acid pathway, through which 
erythrose-4-phosphate and phosphoenol pyruvate is converted 
into chorismic acid. The latter is the precursor of important 
aromatic metabolites such as the aromatic amino acids, folate 
cofactors, ubiquinone and vitamins E and K.2 DHQ2, which is 
encoded by the aroD/aroQ gene, is an essential enzyme in 
Mycobacterium tuberculosis, the causative agent for 
tuberculosis, and Helicobacter pylori, which which is a major 
cause of gastric and duodenal ulcers and it has been classified 
as class I carcinogen by the International Agency of Research 
on Cancer (IARC) and World Health Organization (WHO).3,4 
DHQ2 catalyzes the reversible dehydratation of 3-dehydroquinic 
acid (1) to form 3-dehydroshikimic acid (3) via the enolate 
intermediate 2 (Figure 1).5,6 Extensive biochemical, structural 
and QM/MM studies revealed that the enzymatic reaction is 
initiated by an essential aspartate that deprotonates an essential 
tyrosine to afford the catalytic tyrosinate, which triggers the 
process.5-7 The necessary reduction in pKa of the tyrosine is 
achieved by the proximity of two conserved arginine residues 
and a cation-π interaction with an essential arginine. The final 
step is the acid-catalyzed elimination of the C1 hydroxyl group 
that is mediated by the conserved histidine acting as a proton 
donor.  
Two of the three catalytic residues, Tyr22 and Arg17 for H. pylori 
DHQ2, are located in the substrate-covering loop (catalytic loop) 
that closes the active site after substrate binding (Figure 1A). It 
has been shown that the arrangement of the catalytic loop 
required for catalysis has: (1) the side chains of the tyrosine and 
arginine residues pointing towards the active site; and (2) a 
cation-π interaction between the catalytic residues.5 We believe 
that targeting the loop plasticity is a good strategy for inhibitor 
design since the motion of this loop is an essential process for 
the DHQ2 catalytic cycle. 5,8 We became therefore interested in 
designing ligands able of altering the flexibility of the loop by 
compounds structurally different from previously reported ones, 
which are mainly based on the mechanism of action.7 These 
reported inhibitors are either mimics of the enol intermediate 2, 
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compounds 45,9 or substrate analogs, compounds 610 (Figure 
1D). More recently, several 3-nitrobenzylgallate-based analogs 7 
have been described, which incorporate relevant aromatic 
moieties previously identified by structural and biological 
studies.11 Remarkably, in the crystal structure of DHQ2 in 
complex with the most potent inhibitors is observed that the 
aromatic moiety present in their structure block the entrance of 
the essential arginine side chain into the active site and cause 
an important change in the appropriate arrangement and 
flexibility of the substrate-covering loop.12 These aromatic 
moieties are located in the interface pocket, which separates two 
neighbor subunits of the enzyme and is located at the entrance 
of the active site. DHQ2 is a dodecamer formed from a tetramer 
of trimers, a trimer being the minimum catalytic unit of the 
enzyme.13 QSAR studies also revealed that this pocket is key for 
the efficacy and specificity of inhibitors.14,15  
In particular, we aimed for ligands that would either stabilize the 
closed form avoiding the entrance of the substrate or the open 
conformation providing a widely exposed active site. For our 
goal, we took into account: (1) our previous studies on the 
motion of the catalytic loop during product release pinpointed by 
Molecular Dynamic (MD) simulation studies of the product 
enzyme complex (Figure 1B),5 (2) the loop conformational 
changes observed in the crystal structures of DHQ2 from M. 
tuberculosis (Mt-DHQ2) and H. pylori (Hp-DHQ2) in complex 
with some of the most potent reported inhibitors,6 and (3) the 
well stablished advantages of the fragment-based approaches 
as will be discussed below.16-25  
 
Figure 1 (A) Schematic representation of the DHQ2 enzyme motion required for catalysis. Note the cation-π interaction between the essential tyrosine and 
arginine side chains that are required for catalysis. Both residues must be also pointing towards the active site. Only two chains of the catalytic trimer are shown 
for clarity. (B) RMSD plot for the protein backbone (Cα, C, N, and O atoms) calculated per residue in the DHQ2/3 complex obtained from MD simulations studies 
of the product release (DHQ2/3 enzyme complex).
5
 Note how the loop undergoes a large conformational change during product release whereas no significant 
changes are observed in the rest of the protein. (C) Enzymatic conversion of 3-dehydroquinic acid (1) to 3-dehydroshikimic acid (3) catalyzed by DHQ2. The 
reaction proceeds via the enol intermediate 2. (D) Selected examples of DHQ2 inhibitors.
9-11
 






We aim to identify inhibitors containing drug-like entities that 
might facilitate the entrance into the bacterium cell in which the 
aromatic fragments would be located in the interface pocket to 
block the active site entrance. For this purpose, fragment-based 
screening is nowadays a wide accepted technique to identify 
relatively simple hit-compounds that possess a high binding 
affinity per heavy atom, and thus are ideal compounds for 
optimization into clinical candidates with good drug-like 
properties.16-25 This technique has emerged as an important 
alternative to high-throughput screening,24-25 because it has the 
advantage that incorporates the structural information26 of the 
target to preselect the molecules that are most likely to show 
binding and inhibitory activity. The available experimental 
knowledge of known inhibitors is incorporated by using 
pharmacophore constraints to preselect compounds for docking 
and therefore reducing computation times. Computer-aided 
fragment-based approaches are being increasingly proven as a 
successful means of generating novel hits for drug discovery 
programs.27 In this context, the Anchor-based Library Tailoring 
screening Approach (ALTA), which was developed in 2008 by 
Caflisch et al.,28 has proven to be very efficient for the discovery 
of novel inhibitors of a variety of targets. For instance, it has 
been successfully applied to the discovery of inhibitors of 
tyrosine kinase erythropoietin producing human hepatocellular 
carcinoma receptor B4,28-29 of the West Nile virus NS3 
protease,30 cathepsin B,31 the human cyclin-dependent kinase 
232 and several human bromodomains33. The essential element 
of the ALTA method is the use of optimally docked small 
fragments to select from a large library of compounds only those 
that have one (or more) of the top-ranking fragments.  
Here, we present the computer-aided fragment-based 
identification of reversible competitive inhibitors of a recognized 
target for antibiotic drug discovery, Hp-DHQ2. The synthesis of 
the identified potential compounds and their inhibitory activity 
are also provided. Moreover, chemical modifications on the most 
active compound obtained in this study were also explored for 
further optimization. We provide evidence based on Molecular 
Dynamics (MD) simulation studies that our inhibitors reduce the 
plasticity of the catalytic loop by blocking key residues for the 
catalysis. 
Results and Discussion 
Fragment-based Identification of Ligands 
The subset “clean-leads” of the ZINC database34 with about 1.5 
million compounds was chosen for this study. The computer-
aided fragment-based approach used, ALTA, involves four 
consecutive steps (Figure 2): (1) automatic decomposition of 
each molecule of the chemical library into fragments using the 
program DAIM (Decomposition And Identification of 
Molecules);35 (2) fragment docking using SEED (Solvation 
Energy for Exhaustive Docking) for selection and ranking of the 
fragments;36 (3) substructure search of the ALTA-selected 
fragments into the chemical library for initial selection of potential 
ligands; and (4) flexible docking of each selected compound 
using the best poses of its fragments as anchors for final 
compound selection and ranking. This is carried out using 
FFLD37 (Fast Flexible Ligand Docking) and CHARMM34 for the 
energy minimization of the enzyme-ligand resulting complex. 
Evaluation of the binding free energy of multiple poses of each 
compound makes use of the LIECE (Linear Interaction Energy 
with Continuum Electrostatics) method.39  
To discard at an early stage fragments that are unlikely to bind, 
several pharmacophores constraints were used. In particular, 
considering that the active site of DHQ2 has several residues 
capable of recognizing bidentate groups such as carboxylates or 
sulfonamides, a filtering step discarded all compounds devoid of 
these functional groups. It was also considered that compounds 
should have a maximum of 10 rotatable bonds, between 2 to 6 
acceptor groups, ≤ 3 donor groups and a total number of 
hydrogen-bond acceptor and donor ≤ 10. As a consequence, the 
chemical library was reduced to 239.779 compounds from which 
DAIM extracted 61.549 candidate fragments. 
 
Figure 2 Graphical representation of the workflow of ALTA procedure. 
Docking was carried out using the previously reported enzyme 
structure of Hp-DHQ2 in complex with (1R,4S,5R)-1,4,5-
trihydroxy-3-[(5-methyl-1-benzothiophen-2-yl)methoxy]cyclohex-
2-ene-1-carboxylic acid (4a, 1R = (5-methyl-1-benzothiophen-2-
yl)methoxy), PDB code 2WKS).9m This crystal structure was 
chosen because it has an inappropriate conformation of the 
substrate-covering loop for catalysis. Thus, the aromatic moiety 
in 4a expels the side chain of the essential Arg17 out of the 
active site and, under this arrangement the enzyme is efficiently 
inhibited. After fragment docking, the library of fragments was 
reduced to 10.712 candidate fragments. Using all these 
fragments as queries a subset of 30.309 compounds from the 
initial library was generated. After flexible docking of each 
molecule of the library using the best poses of its fragments as 
anchors, the best 50 top-ranking compounds were selected 
(Table S1). The first two compounds and seven of remaining 
ones, which were selected based on structural considerations of 
the key interactions with the enzyme, were chosen for biological 
evaluation (Figure 3). Compounds 8 and 15–16 were obtained 
from commercial sources and compounds 9–14 were 






synthesized using standard procedures (see a detailed 
description in the Supporting Information). 
 
Inhibition Activity of Compounds 816 
The potential DHQ2 ligands identified by ALTA-approach, 
compounds 816, were assayed in the presence of 3-
dehydroquinic acid (1) for their inhibitory properties against Hp-
DHQ2. The inhibition data are summarized in Table 1. In general, 
these compounds were found to be reversible competitive 
inhibitors of the enzyme with Ki values in the micromolar range, 
below the Km of the enzyme. The most potent inhibitor proved to 
be the quinazolinedione 15 with a Ki of 19 µM. This compound 
clearly stands out from the series as the next ones, specifically 
compounds 9, 14 and 16, showed Ki values between 77 and 91 
µM. 
 
Figure 3 Selected potential inhibitors of the Hp-DHQ2 enzyme obtained by the 
fragment-based approach. 
Binding Mode of Compounds 816  
The binding modes of the most potent identified inhibitors, 
compounds 9 and 1416, revealed that the aromatic ring of the 
ligands 9 and 1416 would be located in the interface pocket 
(Figure 4). The aromatic moiety of compounds 9 and 1416 
should have apolar interactions with the side-chain of Leu93*, 
Met92* and the carbon side-chain of Asp89* (residues from this 
subunit will be marked with an asterisk). The essential Asp89* 
proved to be responsible for the deprotonation of the essential 
Tyr22 to afford the catalytic tyrosinate, which in turn triggers the 
enzymatic process.5 Moreover, several lipophilic interactions 
with the side-chain of Leu11 and Leu14 were also recognized.  
The carboxylate group of the inhibitors would be located in the 
C1 binding pocket by forming hydrogen-bonding interactions 
with the side-chain of Asn76, the main amide chain of Leu103 
and Thr104. This pocket has been proven to be crucial for 
substrate recognition and enzyme catalysis.40 Thus, the 
carboxylate group of the natural substrate interacts with the 
active site through four strong hydrogen bonds involving the 
main chain NH amide group of Leu103 and Thr104, the OH 
group of the side chain of Thr104 side chain and the amide side 
chain of Asn76 (Figure S1). Moreover, two hydrogen bonds with 
the conserved Asn76 and His102 is the way in which the 
enzyme controls the correctly positioning of the C1 hydroxyl 
group for the final elimination step. 
 





8 141 ± 19 
9 77 ± 5 
10 139 ± 12 
11 103 ± 13 
12 159 ± 15 
13 >300  
14 85 ± 5 
15 19 ± 2 
16 91 ± 12 
a
Assay conditions: Tris.HCl (50 mM), pH 7.0, 25 °C.  
Km (1) = 444 μM. 
b
Values are the mean ± SEM of (n = 3) 
determinations. 
 
Remarkably, in addition to the above mentioned interactions, the 
binding modes of the most active inhibitors appear to have in 
common π-π stacking and hydrogen-bonding interactions with 
Tyr22. Specifically, a hydrogen-bond between the phenol group 
of Tyr22 and the amide carbonyl group of ligand 9 or the 
carbonyl group of the aromatic ring of ligands 1416 would take 
place. Tyr22 is the essential residue that removes the pro-R 
hydrogen of C2 in 1 and which appropriate orientation for 
catalysis is controlled by the essential Arg17. This hydrogen-
bonding interaction with Tyr22 is absent in the weakest inhibitors 
of the series, ligands 8 and 1012, (Figure S2). In addition, the 
predicted binding of ligands 8 and 12 would be very different 
from the rest of the tested ligands in this study, which might 
account for its lower potency. However, in both cases, the 
aromatic ring of the ligands would be located in the interface 
pocket. Once the aromatic ring is fixed in this region, the rest of 
the molecule seems to be located in the space available of the 
active site by establishing hydrogen-bonding interactions with 
polar residues of the active site. These results revealed that a 
large number of the aromatic moieties included in the reported 
ligands are well located in the interface pocket and might 
therefore be good hit fragments to be considered in future 
designs.  






In general: (a) ligand 14 would be the only one lacking any 
interactions with the C6C5 substrate recognition center of the 
enzyme involving the conserved residue His82; (b) the 
interaction of the aromatic moiety with the essential Tyr22 and 
the interface pocket in 16 seems to be less efficient than for 
compounds 9 and 1415; and (c) compound 15 would be the 
ligand that would best interact with the main pockets of the 
enzyme, which might explain its higher inhibitory potency. 
Moreover, considering that ligand 9 is structurally very close to 
3-nitrobenzylgallate-based analogs 7, which were reported by 
Abell et al.11 during the realization of the herein presented 
studies, our subsequent efforts were focused on the optimization 
of ligand 15. 
Globally, the most potent inhibitor identified in this study, 
compound 15, contains two key moieties: (i) the 
quinazolinedione ring and (ii) the carboxylate group. Among the 
two, the aromatic ring seems to be particularly well located to 
reduce the flexibility of the substrate-covering loop by interaction 
with the essential tyrosine and the interface pocket. Hence, in 
order to explore the possible improvement of the inhibitory 
activity obtained, the modification of the chain containing the 
carboxylate group in 15 was then studied.  
Four new quinazolinedione derivatives, compounds 17S, 17R, 
and 1819, were designed (Figure 5A). We took into account the 
binding mode of citrate in the crystal structure of Hp-
DHQ2/citrate binary complex (PDB code 2C4V, 2.5 Å) reported 
by Lapthorn et al.41 This compound proved to be a competitive 
inhibitor of the enzyme with a Ki value of 2.5 mM. Compounds 
17S and 17R containing an acetate group instead of an 
isopropyl one were designed to improve the interaction with the 




Figure 4 Selected view of the predicted binding mode of ligands: (A) 9 (yellow), (B) 14 (orange), (C) 15 (green), and (D) 16 (pink) in the Hp-DHQ2 active site. The 
neighboring chain close to the active site is shown in blue and its relevant side chain residues are indicated with an asterisk. Relevant side chain residues are 
shown and labeled. Hydrogen-bonding (red) and lipophilic (grey) interactions are indicated as dashed lines.  







Figure 5 (A) Explored chemical modifications of the carboxylate containing chain in 15. New targeted quinazolinedione derivatives 1719. (B) Synthesis of 
compounds 17S, 17R and 18. Reagents and conditions. (a) N-Boc-ethylenediamine (for 21) or ethyl 4-aminobutaroate (for 22), EDC, DMAP, DMF, RT; (b) 
triphosgene, DIPEA, DCM, RT; (c) TFA, DCM, 0 °C; (d) 1. LiOH, THF, RT. 2. HCl (10%). (e) 1. SOCl2, 60 °C. 2. Dimethyl L-aspartate (for 27S) or Dimethyl D-
aspartate (for 27R), Et3N, DCM, RT; (f) 1. LiOH. 2. Amberlite IR-120 (H
+
); (g) 1. LHMDS, THF, 78 °C; 2. BrCH2CO2
t
Bu, 23 °C; (h) 24, HATU, DIPEA, DMF, RT; 
(i) HCl (4.5 M), RT.  
In addition, reasoning that in the Michaelis complex the C1 
hydroxyl group interacts by hydrogen bonding with the 
conserved Asn76 and His102 to correctly positioning this group 
in the final elimination step (Figure S1),5 the incorporation of a 
tertiary hydroxyl group was also explored with compound 18. 
Finally, considering that the amide linker does not seem to 
interact with the enzyme active site residues, the effect of the 
incorporation of a flexible carbon chain was explored with 
compound 19. 
Chain Optimization – Quinazolinediones derivatives 
1719 
(a) Synthesis  Compounds 17 and 18 were prepared by amide 
coupling between the acids 26 and 30 and the amines dimethyl 
L-aspartate, dimethyl D-aspartate, and 24, respectively (Figure 
5B). Our initial efforts for the synthesis of the 
aminoquinazolinedione 24 involved the nucleophilic substitution 
of commercially available chloride 28 with lithium amide, sodium 
azide or benzylamine, various solvents (DMF, MeCN, Toluene), 
bases (K2CO3, DIPEA) and reaction temperatures (50100 °C). 
However, all the attempts afforded mainly starting material or an 
intramolecular cyclization reaction of 28. The synthesis of the 
amino 24 was finally achieved in three steps from antranilic acid 
(20) by first incorporation of the required chain followed by 
quinazolinedione ring formation. Thus, EDC-condensation with 
commercially available N-Boc-ethylenediamine followed by 
intramolecular condensation of the resulting amide 21 with 
triphosgene and subsequent removal of the Boc protecting 
group in 23 with TFA yielded the required amine 24 as 
trifluoroacetic acid salt. Following a similar strategy, the 
quinazolinedione 26 was prepared from ethyl 4-aminobutaroate 
and antranilic acid (20).  







Scheme 1 (A) Explored olefin cross metathesis strategy for the synthesis of 19. (B) Synthesis of compound 19. Reagents and conditions. (a) 4-bromobutene, 
Grubbs-Hoveyda 2
nd
 catalyts, PhMe, 90 °C; (b) NaN3, DMF, 90 °C; (c) 1. Ph3P, THF, H2O, ∆. 2. 20, EDC, DMAP, RT; (d) triphosgene, Et3N, DCM, RT (e) H2, Pd/C 
(10%), EtOH, RT; (f) 1. LiOH. 2. Amberlite IR-120 (H
+
).  
On the other hand, the required acid 30 for the preparation of 18 
was synthesized following Seebach´s42 self-reproduction of 
chirality synthetic principle. Thus, alkylation with tert-butyl 
bromoacetate of the carbanion resulting of the treatment with 
lithium hexamethylsilazide of previously reported dioxolanone 
acid 2943 afforded the desired compound 30. Next, amide 
coupling between the acids 26 and 30 and the amines dimethyl 
L-aspartate, dimethyl D-aspartate and 24, respectively, using 
HATU as coupling agent and in the presence of 
diisopropylethylamine gave the amides 27S, 27R and 31, 
respectively. Finally, deprotection of latter compounds yielded 
the required amides 17S, 17R and 18, respectively.  
The synthesis of compound 19, in which the quinazolinedione 
and the carboxylic acid moieties are linked through a saturated 
carbon chain, proved to be more challenging. An olefin cross 
metathesis (OCM) approach involving the construction of the 
C4C5 carbon bond was designed (Scheme 1A). This 
disconnection was chosen because it would allow the use of the 
allyl derivative 34,43 which is readily prepared by alkylation with 
allyl bromide of the dioxolanone acid derived from L-malic acid, 
compound 35. Initial alkylation attempts revealed that the use of 
less reactive electrophiles such as long chain alkyl bromides 
provide quite low yields of the required products. 
All the attempts of OCM between the allyl derivatives 33 and 34 
revealed to be unsatisfactory due to the poor selectivity towards 
the required heterodimer product. Homodimerization of 34 was 
the main reaction product whereas compound 33 showed to 
have very low reactivity. Fortunately, the selectivity towards the 
heterodimer product was achieved following the general 
guidelines reported by Grubbs et al.44 consisting in the use of 
two olefins of remarkably different reactivity (Scheme 1B). Thus, 
the OCM between 4-bromobutene (type I olefin) and compound 
34 (type II olefin) catalyzed by second generation of Grubbs-
Hoveyda catalysts gave the cross trans olefin 36 in 71% yield. 
Having incorporated the carbon long chain, the following steps 
were focused in the construction of the quinazolinedione ring. 
First, the bromide 36 was converted into the required amine by 
nucleophilic substitution with sodium azide and subsequent 
Staudinger reduction of the resulting azide 37. The EDC-
coupling of the terminal amine with antranilic acid (20) in the 
presence of 4-N,N-dimethylpyridine gave the amide 38. It is 
important to highlight that the presence of a trans double bond in 
the carbon chain is key for the successful synthesis of the 
aromatic ring. Thus, the conformational restriction induced by 
this olefin avoids the intramolecular nucleophilic attack by the 
resulting amine to the methyl ester. Finally, the intramolecular 






condensation of 38 with triphosgene gave the quinazolinedione 
39 that was transformed into the desired compound 19 by 
catalytic hydrogenation of the double bond and subsequent 
hydrolysis of the resulting saturated compound 40.  
(b) Inhibitory activity of compounds 1719 and 32 The results 
of inhibition activity of compounds 1719 and 32 against Hp-
DHQ2 revealed that reducing the conformational restriction in 
the carbon bearing the carboxylic group, which is involved in the 
recognition in the C1 pocket, enhances the inhibitory potency 
(Table 2). The most favorable effect was achieved with 
compound 19 (Ki = 6.3 µM) having a flexible carbon chain. In 
addition, it seems that the increased flexibility also favors extra 
interactions of the incorporated tertiary hydroxyl and acetate 
groups with residues Asn76, Leu103, His102 and His82, as 
designed. In fact, no significant effects were observed when the 
latter groups were introduced in the ligand having an amide 
linker, compound 18. In order to corroborate: (1) this hypothesis; 
(2) to assess the reliability of the proposed complexes and (3) to 
determine the conformational changes caused in the substrate-
covering loop of Hp-DHQ2 after compound 19 binding, MD 
simulations studies were conducted with the highest score 
solutions obtained by docking for ligands 18 and 19. 
 (c) MD Simulations Studies – The binding modes of ligands 18 
and 19 were first generated by the program GOLD45 version 5.2 
using the same enzyme structure as for the fragment docking, 
i.e., PDB 2WKS9m. The highest score solution for the two Hp-
DHQ2/18 and Hp-DHQ2/19 binary complexes were subjected to 
100 ns of MD simulations at a temperature of 300 K (Figure 6). 
These studies were carried out considering a dual protonation of 
His102 based on mechanistic reasons and the three possible 
protonation states of His82, i.e. dual (δ and ε) and single (δ or ε). 
The best results were obtained with a dual protonation of His82 
because in doing so the carboxylate group is well stabilized 
nearby. Other protonation states provided significant motion on 
the His82 side chain. In addition, similar results were obtained 
from MD simulation studies on the Hp-DHQ2/citrate binary 
complex (PDB code 2C4V). These results explain why in the 
latter structure the electronegative O4 atom of one of the 
carboxylate group in citrate is located at 2.5 Å of the also 
electronegative NE1 atom of His82 residue. 
 






15 19 ± 2 
17S 111 ± 3 
17R 52 ± 5 
18 18 ± 2 
19 6.3 ± 0.2 
32 166 ± 15 
a
Assay conditions: Tris.HCl (50 mM), pH 7.0, 25 °C.  
Km (1) = 444 μM; 
b




Figure 6 Detailed view of the predicted binding of ligands 19 (A, yellow) and 18 (B, green) in the active site of Hp-DHQ2 obtained by MD simulation studies. Both 
poses showed correspond to snapshots after 60 ns of MD simulation. Hydrogen-bonding interactions between ligand and several residues of the active site are 
shown as red dashes. (C) Comparison of the binding mode of ligands 19 and 18 in the active site of Hp-DHQ2. (D-F) Variation of the relative distance between 
resides Arg117 (O atom, D), His102 (ND1 atom, E), and Leu103 (N atom, F) and NH group of the aromatic moiety (N2 and N3 atoms), the medium chain 
carboxylate (O4, O7 and O1 atoms) in 19 and 18, respectively, during the whole simulation. Note how ligand 19 has stronger hydrogen bonding interactions with 






the latter residues than ligand 18 and provides a closer and more organized conformation of the substrate-covering loop. Side chain residues from the neighbor 
chain are shown in cyan and labeled with an asterisk. 
The results clearly show that the flexible carbon chain in 19: (1) 
causes a more pronounced reduction of the flexibility of the 
catalytic loop than in 18 and (2) enhances the strength of the 
hydrogen bonding interactions involving residues Asn76, His102, 
Leu103 and His82. These effects are easily visualized by 
analyzing the variation of the distance between the atoms 
involved in these hydrogen bonds during the 100 ns of 
simulation (Figures 6E-6F and S3). Thus, for ligand 19, the loop 
folds on top of the ligand so that after 20 ns of simulation a 
stable hydrogen bond between the NH group of the aromatic 
moiety and the backbone carbonyl of Arg17 (in the catalytic 
loop) is formed with an average distance of 3.1 Å (distances are 
measured between heavy atoms) (Figures 6C and 6D). In fact, 
our MD studies revealed that in the presence of 19 the loop is 
clearly more ordered (Figure 6C). After the folding, the complex 
is very stable as no significant changes were observed for the 
remaining simulation (Figure S4A). This phenomenon was not 
observed for ligand 18, showing an average distance of 10.9 Å. 
The Hp-DHQ2/18 complex remained unchanged during the 
whole simulation (Figure S4B). 
Moreover, the hydrogen bonds between the hydroxyl and 
carboxylate groups in 19 with the NH groups of His102, Asn76 
and Leu103 have an average distance of 3.4 Å and 3.0 Å, 
respectively. For 18, they are 6.4 Å and 5.7 Å, respectively. 
Therefore, the incorporation of the flexible chain in 19 seems to 
enhance the binding of the carboxylate group of the inhibitor in 
the C1 recognition center. The strength of hydrogen bonds 
involving residue His82 are quite similar (Figure S3). For both 
ligands, the terminal carboxylate group would interact by 
favourable electrostatic interactions with the conserved residues 
Arg109, Arg113 and His82. 
Conclusions and Final Remarks 
A multidisciplinary approach has been employed here to search 
for ligands able to disable the enzyme flexibility that is an 
essential process for catalysis. This has been applied to the 
inhibition of a recognized target for antibiotic discovery, the type 
II dehydroquinase from Helicobacter pylori (Hp-DHQ2), which is 
essential enzyme in this pathogenic bacterium. A computer-
aided fragment-based approach, ALTA, was first employed to 
identify the aromatic fragment able to block the active site 
entrance by binding to the interface pocket that separates two 
neighbor enzyme subunits. The identified quinazolinedione 15 
proved to be a reversible competitive of the Hp-DHQ2 with a Ki 
of 19 µM, below the Km of the enzyme (444 µM). Subsequent 
chemical modification of the non-aromatic moiety in 15 through 
an olefin cross metathesis and Seebach´s self-reproduction of 
chirality synthetic principle allowed the development of a 
quinazolinedione derivative containing a flexible malate moiety, 
compound 19, that seems to efficiently disables the enzyme 
motion. The latter ligand proved to be more potent with a Ki of 
6.3 µM. The results from our Molecular Dynamics simulation 
studies revealed that favoring the geometric perfection in 
anchoring the ligand at the center C1 recognition center, the 
motion of the loop would be frozen by the aromatic fragment and 
consequently the effective inhibition of the enzyme is achieved. 
This would be accomplished by π-π stacking interaction 
between the fragment and the catalytic tyrosine and by 
hydrogen bonding with the main amide group of the essential 
arginine. In doing so, the position of both residues would be well 
fixed in an inappropriate arrangement for catalysis. We also 
believe that some of the fragments identified in this work might 
be also useful hit fragments for future designs if the interaction 
with the C1 carboxylate pocket is improved.  
Experimental Section 
Experimental details on the synthesis of compounds 914 are detailed in 
the supporting information. 
2-Amino-N-[2-(N-Boc)aminoethyl]benzamide (21)  An stirred solution 
of antranilic acid (20) (100 mg, 0.73 mmol) and N-Boc-ethylenediamine 
(0.17 mL, 1.09 mmol) in dry DMF (3.6 mL), under argon and at room 
temperature, was treated with EDC (168 mg, 0.87 mmol) and N,N-
dimethylpyridine (4.4 mg, 0.04 mmol). The resulting mixture was stirred 
at room temperature for 12 h. The reaction mixture was diluted with ethyl 
acetate and water. The organic layer was separated and the aqueous 
phase was extracted with ethyl acetate (×2). The combined organic 
layers were dried (anh. Na2SO4), filtered and concentrated under 
reduced pressure. The residue obtained was purified by flash 
chromatography, eluting with (60:40) ethyl acetate/hexane, to give the 
amide 21 (179 mg, 88%) as a white solid. Mp: 163164 ºC. 1H NMR (300 
MHz, CDCl3) δ: 7.37 (d, J = 7.8 Hz, 1H, ArH), 7.227.14 (m, 1H, ArH), 
6.98 (br s, 1H, NH), 6.63 (m, 2H, 2×ArH), 5.54 (br s, 2H, 2×NH), 5.04 (br 
s, 1H, NH), 3.563.43 (m, 2H, CH2), 3.37 (m, 2H, CH2) and 1.42 (s, 9H, 
C(CH3)3) ppm. 
13C NMR (75 MHz, CDCl3) δ: 170.0 (C), 157.4 (C), 148.9 
(C), 132.4 (CH), 127.6 (CH), 117.4 (CH), 116.7 (CH), 115.7 (C), 80.0 
(C(CH3)3), 41.5 (CH2), 40.2 (CH2) and 28.5 (C(CH3)3) ppm. IR (ATR) υ: 
3445 (NH), 3349 (NH), 1674 (CO) and 1620 (CO) cm1. MS (ESI) m/z: 
302 (MNa+). HRMS calcd for C14H21N3O3Na (MNa
+): 302.1475; found, 
302.1483. 
Ethyl 4-(2-aminobenzamido)butanoate (22)  A solution of ethyl 4-
aminobutaroate (1 g, 5.96 mmol) and dry triethylamine (0.9 mL, 5.96 
mmol) in dry dichloromethane (52 mL) and under inert atmosphere was 
treated at room temperature with EDC (1.26 g, 6.56 mmol) and antranilic 
acid (20) (2.3 g, 11.92 mmol) in three portions during 1.5 h. The reaction 
mixture was washed with aqueous sodium bicarbonate. The organic 
phase was separated and the aqueous layer was extracted with 
dichloromethane (×2). The combined organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. The residue 
obtained was purified by flash chromatography, eluting with (95:5) 
dichloromethane/ethyl acetate, to give the amide 22 (782 mg, 71%) as an 
orange oil. 1H NMR (250 MHz, CDCl3) δ: 7.24 (dd, J = 7.8 and 1.5 Hz, 1H, 
ArH), 7.06 (td, J = 1.5 and 7.0 Hz, 1H, ArH), 6.73 (br s, 1H, NH), 6.55 (dd, 
J = 8.1 and 1.1 Hz, 1H, ArH), 6.49 (td, J = 1.5 and 8.0 Hz, 1H, ArH), 5.22 
(br s, 2H, NH2), 4.00 (q, J = 7.1 Hz, 2H, OCH2), 3.30 (q, J = 6.5 Hz, 2H, 
NCH2), 2.28 (t, J = 7.1 Hz, 2H, COCH2), 1.79 (quint, J = 7.0 Hz, 2H, 
NCH2CH2) and 1.13 (t, J = 7.1 Hz, 3H, CH3) ppm. 
13C NMR (63 MHz, 






CDCl3) δ: 173.5 (C), 169.4 (C), 148.5 (C), 131.9 (CH), 127.2 (CH), 117.0 
(CH), 116.3 (CH), 115.9 (C), 60.4 (OCH2), 39.0 (NCH2), 31.7 (CH2), 24.4 
(CH2) and 14.0 (CH3) ppm. IR (ATR) υ: 3192 (NH), 1719 (CO) and 1625 
(CO) cm1. MS (ESI) m/z: 251 (MH+). HRMS calcd for C13H19N2O3 (MH
+): 
251.1390; found, 251.1385. 
3-[2-(N-Boc)aminoethyl]quinazoline-2,4(1H,3H)-dione (23)  A 
suspension of amide 21 (89 mg, 0.32 mmol) and triphosgene (47 mg, 
0.16 mmol) in dry dichloromethane (1.6 mL), under argon and at room 
temperature, was treated with DIPEA (0.1 mL, 0.64 mmol) and the 
resultant solution was stirred for 1 h. The reaction mixture was diluted 
with dichloromethane and saturated aqueous solution of NaHCO3. The 
aqueous layer was separated and the organic phase was washed with 
water. The organic extract was dried (anh. Na2SO4), filtered and 
concentrated under reduced pressure. The residue obtained was purified 
by flash chromatography, eluting with (75:25) ethyl acetate/hexane, to 
give the quinazolinedione 23 (58 mg, 60%) as a white solid. Mp: 204205 
ºC. 1H NMR (300 MHz, DMSO-d6) δ: 11.35 (br s, 1H, NH), 7.92 (dd, J = 
7.9 and 1.1 Hz, 1H, ArH), 7.657.60 (m, 1H, ArH), 7.207.14 (m, 2H, 
2×ArH), 6.82 (t, J = 5.8 Hz, 1H, NH), 3.97 (t, J = 5.8 Hz, 2H, CH2), 3.19 (t, 
J = 5.8 Hz, 2H, CH2) and 1.28 (s, 9H, C(CH3)3) ppm. 
13C NMR (63 MHz, 
DMSO-d6) δ: 162.2 (C), 155.8 (C), 150.4 (C), 139.6 (C), 134.8 (CH), 
127.4 (CH), 122.3 (CH), 115.0 (CH), 114.0 (C), 77.5 (C(CH3)3), 40.2 
(CH2), 37.7 (CH2) and 28.2 (C(CH3)3) ppm. IR (ATR) υ: 3372 (NH), 1703 
(CO), 1671 (CO) and 1648 (CO) cm1. MS (ESI) m/z: 328 (MNa+). HRMS 
calcd for C15H19N3O4Na (MNa
+): 328.1268; found, 328.1262. 
3-(2-Aminoethyl)quinazoline-2,4(1H,3H)-dione trifluoroacetic acid 
salt (24)  A suspension of protected amine 23 (50 mg, 0.16 mmol) in 
dichloromethane (1.3 mL) at 0 ºC was treated with TFA (1.3 mL) and the 
resultant solution was stirred for 3 h. The reaction mixture was diluted 
with dichloromethane and water. The organic phase was separated and 
the aqueous phase was washed with dichloromethane. The aqueous 
extract was lyophilised to give the amine trifluoroacetic acid salt 24 (50 
mg, 99%) as a white solid. Mp: 253255 ºC. 1H NMR (300 MHz, CD3OD) 
δ: 8.03 (dd, J = 7.9 and 1.0 Hz, 1H, ArH), 7.677.62 (m, 1H, ArH), 
7.207.25 (m, 1H, ArH), 7.17 (d, J = 8.2 Hz, 1H, ArH), 4.32 (t, J = 5.5 Hz, 
2H, CH2) and 3.26 (t, J = 5.5 Hz, 2H, CH2) ppm. 
13C NMR (63 MHz, 
CD3OD) δ: 165.3 (C), 153.1 (C), 141.4 (C), 137.0 (CH), 129.3 (CH), 
124.6 (CH), 116.7 (CH), 115.9 (C), 40.4 (CH2) and 39.9 (CH2) ppm. IR 
(film) υ: 3014 (NH), 1720 (CO), 1687 (CO) and 1654 (CO) cm1. MS 
(ESI) m/z: 204 (MH). HRMS calcd for C10H10N3O2 (MH): 204.0779; 
found, 204.0782. 
Ethyl 3-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)propanoate (25)  
A solution of the amine 22 (50 mg, 0.26 mmol) and triethylamine (72 µL, 
0.52 mmol) in dry dichloromethane (1.3 mL), under inert atmosphere and 
at room temperature, was treated with a solution of triphosgene in dry 
dichloromethane (0.3 mL, 0.16 mmol, 0.2 M). The resulting solution was 
stirred for 2 h and then washed with HCl (10%, ×3). The aqueous phase 
was extracted with dichloromethane (×3). The combined organic extracts 
were dried (anh. Na2SO4), filtered and concentrated under reduced 
pressure. The residue obtained was purified by flash chromatography, 
eluting with (40:10) diethyl ether/hexane, to give the quinazolinedione 25 
(51 mg, 71%) as a yellow solid. Mp: 270271 ºC. 1H NMR (250 MHz, 
CDCl3) δ: 10.85 (br s, 1H, NH), 8.07 (d, J = 7.8 Hz, 1H, ArH), 7.61 (td, J = 
1.3 and 8.2Hz, 1H, ArH), 7.20 (m, 2H, 2×ArH), 4.12 (t, J = 6.8 Hz, 2H, 
NCH2), 4.05 (q, J = 7.1 Hz, 2H, OCH2), 2.43 (t, J = 7.5 Hz, 2H, COCH2), 
2.08 (quint, J = 7.1 Hz, 2H, NCH2CH2) and 1.21 (t, J = 7.1 Hz, 3H, CH3) 
ppm. 13C NMR (63 MHz, CDCl3) δ: 172.8 (C), 162.3 (C), 152.2 (C), 138.5 
(C), 134.9 (CH), 128.1 (CH), 123.2 (CH), 115.1 (CH), 114.4 (C), 60.3 
(OCH2), 40.1 (NCH2), 31.7 (CH2), 23.1 (CH2) and 14.0 (CH3) ppm. IR 
(ATR) υ: 2955 (NH), 1729 (CO) and 1620 (CO) cm1. MS (ESI) m/z: 299 
(MNa+). HRMS calcd for C14H16N2O4Na (MNa
+): 299.1002; found, 
299.1013. 
3-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)propanoic acid (26)  A 
solution of the ester 25 (200 mg, 0.73 mmol) in dry THF (1.5 mL) at room 
temperature was treated with aqueous LiOH (2.1 mL, 0.7 M). The 
reaction mixture was stirred at room temperature for 2 h and then 
washed with diethyl ether. The aqueous phase was acidified with HCl 
(10%) and extracted with ethyl acetate (×3). The combined organic 
extracts were dried (anh. Na2SO4), filtered and concentrated under 
reduced pressure to give the acid 26 (158 mg, 90%) as a white solid. Mp: 
247249 ºC. 1H NMR (250 MHz, CD3OD) δ: 8.03 (d, J = 7.9 Hz, 1H, ArH), 
7.64 (t, J = 7.6 Hz, 1H, ArH), 7.23 (t, J = 7.6 Hz, 1H, ArH), 7.16 (d, J = 
8.2 Hz, 1H, ArH), 4.09 (t, J = 6.9 Hz, 2H, NCH2), 2.39 (t, J = 7.3 Hz, 2H, 
COCH2) and 1.99 (quint, J = 7.1 Hz, 2H, NCH2CH2) ppm. 
13C NMR (63 
MHz, CD3OD) δ: 176.6 (C), 164.3 (C), 152.3 (C), 140.7 (C), 136.1 (CH), 
128.7 (CH), 123.9 (CH), 116.0 (CH), 115.4 (C), 41.1 (NCH2), 32.3 (CH2) 
and 24.3 (CH2) ppm. . IR (ATR) υ: 3431 (NH+OH), 1707 (CO), 1688 (CO) 
and 1650 (CO) cm1. MS (ESI) m/z: 247 (MH). HRMS calcd for 
C12H11N2O4 (MH): 247.0724; found, 247.0721. 
Diester 27S  A solution of the acid 26 (80 mg, 0.3 mmol) in tionyl 
chloride (5 mL) was heated under reflux for 30 min. After cooling to room 
temperature, the solvent was removed under reduced pressure and the 
crude residue was dissolved in dry dichloromethane (2 mL) and treated 
with dry trimethylamine (80 µL, 0.6 mmol) and dimethyl L-aspartate (60 
mg, 0.3 mmol). The resulting mixture was stirred at room temperature for 
2 h and then washed with saturated NaHCO3 (×3) and brine (×3). The 
organic extract was dried (anh. Na2SO4), filtered and concentrated under 
reduced pressure. The resulting residue was purified by flash 
chromatography, eluting with ethyl acetate, to give the diester 27S (78 
mg, 66%) as a white foam. [α]D
20 = +27.0º (c1.1, CHCl3). 
1H NMR (500 
MHz, CDCl3) δ: 10.01 (s, 1H, NH), 8.09 (dd, J = 0.7 and J = 7.9 Hz, 1H, 
ArH), 7.60 (td, J = 1.4 and J = 8.2 Hz, 1H, ArH), 7.21 (t, J = 7.5 Hz, 1H, 
ArH), 7.13 (d, J = 8.1 Hz, 1H, ArH), 7.01 (br d, J = 8.5 Hz, 1H, NH), 4.89 
(dt, J = 4.6 and J = 8.1 Hz, 1H, CH), 4.16 (m, 2H, NCH2), 3.73 (s, 3H, 
OCH3), 3.68 (s, 3H, OCH3), 3.02 (dd, J = 4.7 and J = 17.1 Hz, 1H, 
CHHCO2Me), 2.87 (dd, J = 4.6 and J = 17.1 Hz, 1H, CHHCO2Me), 2.36 
(m, 2H, CH2CO) and 2.10 (quint, J = 7.0 Hz, 2H, CH2CH2CH2) ppm. 
13C 
NMR (63 MHz, CDCl3) δ: 172.2 (C), 171.4 (C), 171.2 (C), 162.5 (C), 
151.7 (C), 138.6 (C), 134.9 (CH), 128.1 (CH), 123.1 (CH), 115.0 (CH), 
114.2 (C), 52.6 (OCH3), 51.9 (OCH3), 48.4 (CH), 40.0 (NCH2), 36.0 (CH2), 
33.4 (CH2) and 23.9 (CH2) ppm. IR (ATR) υ: 3283 (NH), 1722 (CO) and 
1645 (CO) cm1. MS (ESI): 392 (MH+). HRMS calcd for C18H22N3O7 
(MH+): 392.1452; found, 392.1452. 
Diester 27R  The compound was prepared as its enantiomer 27S using 
the acid 26 (60 mg, 0.2 mmol), tionyl chloride (3.5 mL), dry 
dichloromethane (1.6 mL), dry trimethylamine (67 µL, 0.4 mmol) and 
dimethyl D-aspartate (48 mg, 0.4 mmol). Yield = 59 mg (63%, white 
foam). The compound has the same NMR data as its enantiomer 27S. 
[α]D
20  = 25.0º (c1.1, CHCl3). MS (ESI): 392 (MNa
+). HRMS calcd for 
C18H21N3O7Na (MNa
+): 414.1272; found, 414.1268. 
Diacid 17S  A stirred solution of diester 27S (30 mg, 0.1 mmol) in THF 
(1 mL) was treated with LiOH (0.3 mL, 0.6 mmol, 2.5 M). The resulting 
mixture was stirred at room temperature for 2 h. The reaction mixture 
was diluted with water and THF was concentrated under reduced 
pressure. The aqueous solution was washed with ethyl acetate (3). The 
aqueous phase was treated with Amberlite IR-120 (H+) until pH 6.0 and 
filtered. The filtrate and the washings were freeze-dried to afford 
compound 17S (22 mg, 79%) as a white solid. Mp: 165.3–165.7 ºC. [α]D
20 
= +10.2º (c0.8, H2O). 
1H NMR (300 MHz, D2O) δ: 7.83 (d, J = 8.0 Hz, 1H, 
ArH), 7.64 (t, J = 7.2 Hz, 1H, ArH), 7.23 (t, J = 7.4 Hz, 1H, ArH), 7.06 (d, 






J = 8.2 Hz, 1H, ArH), 4.61 (t, J = 5.9 Hz, 1H, CH), 3.93 (t, J = 7.0 Hz, 2H, 
NCH2), 2.85 (d, J = 6.1 Hz, 2H, CH2CO2H), 2.39 (t, J = 7.3 Hz, 2H, 
CH2CO) and 1.95 (quint, J = 7.1 Hz, 2H, CH2CH2CH2) ppm. 
13C NMR (63 
MHz, D2O) δ: 177.8 (C), 177.2 (C), 177.1 (C), 166.6 (C), 154.1 (C), 140.9 
(C), 138.2 (CH), 129.6 (CH), 126.1 (CH), 117.6 (CH), 115.9 (C), 52.0 
(CH), 42.8 (CH2), 38.5 (CH2), 35.3 (CH2) and 25.5 (CH2) ppm. IR (ATR) 
υ: 3249 (OH+NH), 1704 (CO), 1644 (CO) and 1622 (CO) cm1. MS (ESI): 
362 (M–H). HRMS calcd for C16H16N3O7 (M–H): 362.0994; found, 
362.0993. 
Diacid 17R  The compound was prepared as its enantiomer 17R using 
the diester 27R (70 mg, 0.17 mmol), THF (1.8 mL), and LiOH (0.34 mL, 
2.5 M). Yield = 50 mg (79%, white solid). The compound has the same 
NMR data as its enantiomer 17S. [α]D
20 = 10.1º (c0.8, H2O). MS (ESI): 
362 (M–H). HRMS calcd for C16H16N3O7 (M–H): 362.0994; found, 
362.0994. 
Acid 30  A solution of 2-((2R,4R)-2-(tert-butyl)-5-oxo-1,3-dioxolan-4-
yl)acetic acid (29)40 (300 mg, 1.48 mmol) in dry THF (14.8 mL), under 
argon and at 78 ºC, was treated with LHMDS (2.97 mL, 2.97 mmol, ca 
1M in THF). After 30 min, a solution of tert-butyl bromoacetate (0.33 mL, 
2.22 mmol) in dry THF (3 mL) was added. The reaction mixture was 
allowed to warm up to 23 ºC and it was stirred at this temperature for 
another 10 h. HCl (1 M) was added and the reaction mixture was 
extracted with ethyl acetate (×3). All the organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. Purification 
by flash chromatography, eluting with (91:8:1) 
dichloromethane/methanol/trimethylamine, gave the ester 30 (164 mg, 
35%) as a white solid. [α]D
20 = +18° (c 1.7, CH3OH). 
1H NMR (250 MHz, 
CDCl3) δ: 5.30 (s, 1H, CH), 3.03 (d, J = 16.1 Hz, 1H, CHH), 2.95 (d, J = 
15.6 Hz, 1H, CHH), 2.87 (d, J = 16.1 Hz, 1H, CHH), 2.85 (d, J = 15.6 Hz, 
1H, CHH), 1.16 (s, 9H, C(CH3)3) and 0.96 (s, 9H, C(CH3)3) ppm. 
13C 
NMR (63 MHz, CDCl3) δ: 174.0 (C), 173.1 (C), 168.3 (C), 110.0 (CH), 
82.5 (C), 77.5 (C), 41.3 (CH2), 40.6 (CH2), 34.6 (C(CH3)3), 28.1 (C(CH3)3) 
and 23.7 (C(CH3)3) ppm. IR (KBr) υ: 3009 (OH), 1806 (CO), 1724 (CO) 
and 1708 (CO) cm1. MS (ESI) m/z: 315 (M–H). HRMS calcd for 
C15H23O7 (M–H): 315.1449; found, 315.1456. 
Amide 31  A stirred solution of acid 30 (16 mg, 0.05 mmol) and amine 
24 (24 mg, 0.12 mmol) in dry DMF (3.6 mL), under argon and at room 
temperature, was treated with HATU (36 mg, 0.09 mmol) and DIPEA (8.5 
µL, 0.05 mmol). The resulting mixture was stirred at room temperature for 
1 h. The reaction mixture was diluted with ethyl acetate and water. The 
organic layer was separated and the aqueous phase was extracted with 
ethyl acetate (×2). The combined organic layers were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. The residue 
obtained was purified by flash chromatography, eluting with (75:25) ethyl 
acetate/hexane, to give the amide 31 (15 mg, 60%) as a white solid. Mp: 
203205 ºC. [α]D
20 = +6.7º (c 1.0, CHCl3). 
1H NMR (300 MHz, CDCl3) δ: 
10.3 (br s, 1H, NH), 8.05 (dd, J = 8.0 and 1.0 Hz, 1H, ArH), 7.68 (m, 1H, 
ArH), 7.16 (m, 2H, 2×ArH), 6.94 (t, J = 5.0 Hz, 1H, NH), 5.26 (s, 1H, CH), 
4.27 (t, J = 5.5 Hz, 2H, CH2), 3.753.55 (m, 2H, CH2), 2.99 (t, J = 16.6 Hz, 
1H, CHH), 2.99 (d, J = 16.6 Hz, 1H, CHH), 2.89 (d, J = 16.6 Hz, 1H, 
CHH), 2.67 (d, J = 14.7 Hz, 1H, CHH), 2.60 (d, J = 14.7 Hz, 1H, CHH), 
1.41 (s, 9H, C(CH3)3) and 0.89 (s, 9H, C(CH3)3) ppm. 
13C NMR (75 MHz, 
CDCl3) δ: 173.8 (C), 168.9 (C), 167.8 (C), 163.2 (C), 151.9 (C), 138.9 (C), 
135.4 (CH), 128.4 (CH), 123.5 (CH), 115.5 (CH), 114.3 (C), 110.2 (CH), 
82.3 (C(CH3)3), 78.0 (C(CH3)3) 44.2 (CH2), 40.9 (CH2), 40.0 (CH2), 39.3 
(CH2), 34.5 (C), 28.1 (C(CH3)3) and 23.7 (C(CH3)3) ppm. IR (ATR) υ: 
3512 (OH), 3362 (NH), 1793 (CO), 1724 (CO) and 1659 (CO) cm1. MS 
(ESI) m/z: 526 (MNa+). HRMS calcd for C25H33N3O8Na (MNa
+): 
526.2160; found, 526.2168. 
Ester 32  A stirred solution of ketal 31 (40 mg, 0.08 mmol) in water (0.3 
mL) was treated with LiOH (0.7 mL, 0.08 mmol, 0.11 M). The resulting 
mixture was stirred at room temperature for 4 h. The reaction mixture 
was diluted with ethyl acetate and water. The organic layer was 
separated and the aqueous phase was washed with ethyl acetate (×2). 
The aqueous phase was treated with Amberlite IR-120 (H+) until pH 6.0 
and filtered. The filtrate and the washings were freeze-dried to afford 
compound 32 (30 mg, 88%) as a white solid. Mp: 170 ºC (dec.). [α]D
20 = 
0.6° (c 0.9, CH3CN). 
1H NMR (300 MHz, D2O) δ: 7.74 (d, J = 7.9 Hz, 1H, 
ArH), 7.52 (t, J = 7.8 Hz, 1H, ArH), 7.11 (t, J = 7.7 Hz, 1H, ArH), 6.96 (d, 
J = 8.2 Hz, 1H, ArH), 3.94 (t, J = 5.7 Hz, 2H, NCH2), 3.62 (t, J = 5.7 Hz, 
2H, NCH2), 2.70 (t, J = 15.4 Hz, 1H, CHH), 2.51 (d, J = 14.5 Hz, 1H, 
CHH), 2.41 (d, J = 15.4 Hz, 1H, CHH), 2.37 (d, J = 14.5 Hz, 1H, CHH) 
and 1.25 (s, 9H, C(CH3)3) ppm. 
13C NMR (63 MHz, D2O) δ: 172.5 (C), 
171.8 (C), 165.1 (C), 152.5 (C), 139.2 (C), 136.5 (CH), 127.9 (CH), 124.3 
(CH), 116.7 (C), 115.9 (CH), 114.1 (C), 83.7 (C), 74.8 (C), 45.6 (CH2), 
44.8 (CH2), 40.6 (CH2), 37.7 (CH2) and 27.7 (C(CH3)3) ppm. IR (ATR) υ: 
3440, 3125 and 3355 (OH+NH), 1729, 1710, 1668 and 1652 (CO) cm1. 
MS (ESI) m/z: 434 (MH). HRMS calcd for C20H24N3O8 (MH): 434.1569; 
found, 434.1566. 
Acid 18  A stirred solution of ester 32 (10 mg, 0.02 mmol) in water (0.11 
mL) was treated with aqueous HCl (0.08 mL, 0.37 mmol, 4.5 M). The 
resulting mixture was stirred at room temperature for 6 h. The reaction 
mixture was diluted with ethyl acetate and water. The organic layer was 
separated and the aqueous phase was washed with ethyl acetate (×2). 
The aqueous phase was freeze-dried to afford the acid 18 (7 mg, 78%) 
as a white solid. Mp: 151152 ºC. [α]D
20 = +1.6° (c 0.8, H2O). 
1H NMR 
(500 MHz, D2O) δ: 7.83 (d, J = 8.0 Hz, 1H, ArH), 7.56 (t, J = 7.7 Hz, 1H, 
ArH), 7.15 (t, J = 7.7 Hz, 1H, ArH), 7.05 (d, J = 8.3 Hz, 1H, ArH), 3.99 (m, 
2H, NCH2), 3.443.32 (m, 2H, NCH2), 2.77 (t, J = 16.1 Hz, 1H, CHH), 
2.52 (d, J = 15.3 Hz, 2H, CHH+CHH) and 1.25 (d, J = 14.6 Hz, 1H, CHH) 
ppm. 13C NMR (100 MHz, D2O) δ: 176.4 (C), 173.3 (C), 171.1 (C), 164.3 
(C), 151.7 (C), 138.4 (C), 135.7 (CH), 127.1 (CH), 123.6 (CH), 115.1 
(CH), 113.3 (C), 73.3 (C), 44.4 (CH2), 42.6 (CH2), 39.9 (CH2) and 36.9 
(CH2) ppm. IR (ATR) υ: 3264, 3095, 2917 and 2850 (OH+NH), 1704, 
1644 and 1622 (CO) cm1. MS (ESI) m/z: 378 (MH). HRMS calcd for 
C16H16N3O8 (MH): 378.0943; found, 378.0942. 
3-allylquinazoline-2,4(1H,3H)-dione (33)  A suspension of N-allyl-2-
aminobenzamide (50 mg, 0.26 mmol), which was prepared as indicated 
below, in dry dichloromethane (1.3 mL), under inert atmosphere and at 
room temperature, was treated with triphosgene (38 mg, 0.13 mmol) and 
DIPEA (0.1 mL, 0.052 mmol). The resulting solution was stirred for 1 h 
and then diluted with dichloromethane and saturated solution of NaHCO3. 
The aqueous phase was separated and the organic layer was washed 
with water. The organic extract was dried (anh. Na2SO4), filtered and 
concentrated under reduced pressure. The residue obtained was purified 
by flash chromatography, eluting with (75:25) ethyl acetate/hexane, to 
give the quinazolinedione 33 (35 mg, 61%) as a yellow solid. Mp: 
221224 ºC. 1H NMR (300 MHz, CDCl3) δ: 10.82 (br s, 1H, NH), 8.26 (d, 
J = 7.9 Hz, 1H, ArH), 7.61 (t, J= 8.1 Hz, 1H, ArH), 7.23 (d, J = 7.9 Hz, 1H, 
ArH), 7.17 (t, J = 8.1 Hz, 1H, ArH), 5.955.82 (m, 1H CH=CH2), 
5.125.01 (m, 2H, CH=CH2), 4.19 (t, J= 7.1 Hz, 2H, CH2) and 2.51 (q, J = 
7.1 Hz, 2H, CH2) ppm. 
13C NMR (63 MHz, CDCl3) δ: 162.3 (C), 152.4 (C), 
138.7 (C), 134.9 (C), 134.8 (CH), 128.3 (C), 123.3 (C), 117.1 (C), 115.1 
(C), 114.6 (CH2), 40.2 (CH2) and 32.9 (CH2) ppm. IR (ATR) υ: 3183 (NH), 
1714 (CO) and 1629 (CO) cm1. MS (ESI) m/z: 217 (MH+). HRMS calcd 
for C12H13N2O2 (MH
+): 217.0972; found, 217.0969. 
N-allyl-2-aminobenzamide  An stirred solution of antranilic acid (30) 
(100 mg, 0.73 mmol) in dry DMF (3.6 mL), under argon and at room 
temperature, was treated with EDC (168 mg, 0.87 mmol), N,N-
dimethylpyridine (4.8 mg, 0.04 mmol), DIPEA (0.25 mL, 0.15 mmol) and 






3-butenylamine (120 mg, 0.11 mmol). The resulting mixture was stirred at 
room temperature for 1 h. The reaction mixture was diluted with ethyl 
acetate and water. The organic layer was separated and the aqueous 
phase was extracted with ethyl acetate (×2). The combined organic 
layers were dried (anh. Na2SO4), filtered and concentrated under 
reduced pressure. The residue obtained was purified by flash 
chromatography, eluting with (20:800) ethyl acetate/hexane, to give N-
allyl-2-aminobenzamide (105 mg, 70%) as a white solid. Mp: 181−184 ºC. 
1H NMR (300 MHz, CDCl3) : 7.28−7.25 (d, J = 7.8 Hz, 1H, ArH), 
7.19−7.13 (t, J = 7.7 Hz, 1H, ArH), 6.64 (d, J = 8.8 Hz, 1H, ArH), 6.59 (t, 
J = 8.2 Hz, 1H, ArH), 6.27 (br s, 1H, NH), 5.86−5.72 (m, 1H, CH=CH2), 
5.48 (br s, 2H, NH2), 5.15−5.07 (m, 2H, HC=CH2), 3.44 (q, J = 6.4 Hz, 2H, 
CH2) and 2.32 (q, J = 6.7 Hz, 2H, CH2) ppm. 
13C NMR (63 MHz, CDCl3) 
δ: 169.2 (C), 148.6 (C), 135.3 (C), 132.1 (CH), 127.1 (CH), 117.3 (CH), 
117.2 (CH), 116.6 (CH2), 116.3 (C), 38.5 (CH) and 33.7 (CH2) ppm. IR 
(ATR) υ: 3295 (NH) and 1616 (CO) cm1. MS (ESI) m/z: 191 (MH+). 
HRMS calcd for C11H15N2O (MH
+): 191.1179; found, 191.1178. 
Methyl (2S,4S)-2-[(E)-4-(5-bromo-2-pentenyl)-2-(tert-butyl)-5-oxo-1,3-
dioxolan-4-yl)]acetate (36)  A solution of alkene 3443 (160 mg, 0.62 
mmol) and 4-bromobutene (63 μL, 0.62 mmol) in dry toluene (3 mL) 
under inert atmosphere was treated with second generation Grubbs-
Hoveyda catalyst (78 μg, 0.12 mmol) and heated at 90 ºC for 16 h. After 
cooling to room temperature, the reaction mixture was filtered through 
Celite. The filtrate and the washings were concentrated under reduced 
pressure and the resulting brown oil was purified by flash 
chromatography, eluting with (50:50) diethyl ether/hexane, to yield the 
bromide 36 (185 mg, 77%) as a yellow oil. [α]D
20 = +2.2º (c1.0, CHCl3). 
1H 
NMR (250 MHz, CDCl3) δ: 5.625.50 (m, 2H, CH=CH), 5.19 (s, 1H, CH), 
3.63 (s, 3H, OCH3), 3.37 (t, J = 6.6 Hz, 2H, BrCH2), 2.78 (s, 2H, CH2CO2), 
2.61–2.48 (m, 4H, CH2CH=CHCH2), and 0.90 (s, 9H, 3×CH3) ppm.
 13C 
NMR (63 MHz, CD3OD) δ: 173.5 (C), 168.6 (C), 133.2 (CH), 124.8 (CH), 
108.1 (CH), 79.9 (C), 51.9 (OCH3), 39.7 (CH2), 37.0 (CH2), 35.5 (CH2), 
34.1 (C(CH3)3), 32.1 (CH2) and 23.4 (3×CH3) ppm. IR (ATR) υ: 1795 
(CO) and 1743 (CO) cm1. MS (ESI) m/z: 385 and 387 (MNa+). HRMS 
calcd for C15H23Br
79O5Na (MNa
+): 385.0621; found, 385.0621. 
Methyl (2S,4S)-4-[(E)-4-(5-azido-2-pentenyl)]-2-(tert-butyl)-5-oxo-1,3-
dioxolan-4-yl)acetate (37)  A solution of bromide 36 (60 mg, 0.15 
mmol), sodium azide (40 mg, 0.62 mmol) in dry DMF (4 mL) under inert 
atmosphere was heated at 90 ºC for 2 h. After cooling to room 
temperature, the reaction mixture was diluted with ethyl acetate and 
water (1:4). The organic layer was separated and the aqueous layer was 
extracted with ethyl acetate (×3). The combined organic extracts were 
washed with water, dried (anh. Na2SO4), filtered and concentrated under 
reduced pressure. The resulting residue was purified by flash 
chromatography, eluting with (50:50) diethyl ether/hexane, to afford the 
azide 37 (39 mg, 74%) as a colorless oil. [α]D
20 = +10.4º (c1.0, CHCl3). 
1H 
NMR (250 MHz, CDCl3) δ: 5.585.51 (m, 2H, HC=CH), 5.18 (s, 1H, CH), 
3.63 (s, 3H, OCH3), 3.29 (t, J = 6.6 Hz, 2H, N3CH2), 2.77 (s, 2H, 
CH2CO2), 2.50–2.48 (m, 2H, CH2CH), 2.34–2.27 (q, J = 6.2 Hz, 2H, 
CHCH2) and 0.91 (s, 9H, 3×CH3) ppm.
 13C NMR (63 MHz, CDCl3) δ: 
173.4 (C), 168.6 (C), 132.4 (CH), 124.8 (CH), 108.2 (CH), 79.9 (C), 51.9 
(OCH3), 50.5 (CH2), 39.6 (CH2), 37.0 (CH2), 34.1 (C(CH3)3), 32.0 (CH2) 
and 23.4 (3×CH3) ppm. IR (ATR) υ: 2095 (N3), 1798 and 1746 (CO) cm
1. 
MS (ESI) m/z: 348 (MNa+). HRMS calcd for C15H23N3O5Na (MNa
+): 
348.1530; found, 348.1530. 
Methyl (2S,4S)-4-[(E)-5-(2-aminobenzamido)-2-pentenyl]-2-(tert-
butyl)-5-oxo-1,3-dioxolan-4-ylacetate (38)  A solution of azide 37 (170 
mg, 0.6 mmol) in tetrahydrofuran (15 mL) was treated with 
triphenylphosphine (180 mg, 0.6 mmol) and distilled water (0.15 mL) and 
heated under reflux for 12 h. After cooling to room temperature, the 
solvent was removed under reduced pressure. The resulting crude 
mixture was dissolved under inert atmosphere in dry dichloromethane 
(2.5 mL) and then treated with EDC (340 mg, 1.7 mmol), DMAP (53 mg, 
0.4 mmol) and anthranilic acid (20) (130 mg, 0.4 mmol). The resulting 
mixture was stirred at room temperature for 1 h and then diluted with 
dichloromethate and saturated sodium bicarbonate. The aqueous layers 
were extracted with dichloromethane (3). The combined organic 
extracts were washed with water, dried (anh. Na2SO4), filtered and 
concentrated under reduced pressure. The resulting residue was purified 
by flash chromatography, eluting with (4:1) diethyl ether/ethyl acetate, to 
give the amide 38 (105 mg, 74%) as a white foam. [α]D
20 = –5.8º (c1.0, 
CHCl3). 
1H NMR (250 MHz, CDCl3) δ: 7.35 (d, J = 8.0 Hz, 1H, ArH), 7.17 
(t, J = 7.7 Hz, 1H, ArH), 6.67 (d, J = 8.1 Hz, 1H, ArH), 6.60 (t, J = 7.3 Hz, 
1H, ArH), 6.44 (br s, 1H, NH), 5.66–5.40 (m, 3H, NH+CH=CH), 5.18 (s, 
1H, CH), 3.63 (s, 3H, OCH3), 3.573.30 (m, 2H, NHCH2), 2.73 (s, 2H, 
CH2CO2), 2.50 (d, J = 6.8 Hz, 2H, NCH2CH2) 2.32 (q, J = 6.6 Hz, 2H, 
HC=CHCH2), and 0.92 (s, 9H, 3×CH3) ppm.
 13C NMR (63 MHz, CDCl3) δ: 
173.2 (C), 169.2 (C), 168.5 (C), 148.2 (C), 133.8 (CH), 132.0 (CH), 127.1 
(CH), 124.0 (CH), 117.2 (CH), 116.7 (CH), 116.0 (C), 107.9 (CH), 80.0 
(C), 51.9 (OCH3), 39.2 (CH2), 38.5 (CH2), 36.6 (CH2), 34.1 (C(CH3)3), 
32.6 (CH2) and 23.4 (3×CH3) ppm. IR (ATR) υ: 3168 (NH), 3096 (NH), 
1773 (CO) and 1738 (CO) cm1. MS (ESI) m/z: 419 (MH+). HRMS calcd 
for C22H31N2O6 (MH
+): 419.2177; found, 419.2180. 
Quinazolinedione 39  A solution of the aniline 38 (40 mg, 0.1mmol) 
and triethylamine (27 µL, 0.2 mmol) in dry dichloromethane (0.5 mL), 
under inert atmosphere and at room temperature, was treated with a 
solution of triphosgene (18 mg, 0.06 mmol) in dry dichloromethane (0.3 
mL). The reaction mixture was stirred at room temperature for 2 h and 
then washed with HCl (10%, 3). The combined aqueous layers were 
extracted with dichloromethane (3). The combined organic extracts 
were washed with water, dried (anh. Na2SO4), filtered and concentrated 
under reduced pressure. The resulting residue was purified by flash 
chromatography, eluting with (4:1) diethyl ether/ethyl acetate, to afford 
the quinazolinedione 39 (31 mg, 70%) as a white foam. [α]D
20 = +5.7º 
(c1.25, CHCl3). 
1H NMR (300 MHz, CDCl3) δ: 9.85 (br s, 1H, NH), 8.11 (d, 
J = 7.9 Hz, 1H, ArH), 7.60 (td, J = 1.5 and 7.4 Hz, 1H, ArH), 7.22 (td, J = 
0.9 and 8.0 Hz, 1H, ArH), 7.10 (d, J = 8.0 Hz, 1H, ArH), 5.71 (m, 1H, 
CH=CH), 5.44 (m, 1H, CH=CH), 5.11 (s, 1H, CH), 4.15 (t, J = 7.0 Hz, 2H, 
NCH2), 3.63 (s, 3H, OCH3), 2.76 (s, 2H, CH2CO2), 2.50–2.41 (m, 4H, 
CH2CH=CHCH2) and 0.87 (s, 9H, 3CH3) ppm.
 13C NMR (63 MHz, 
CDCl3) δ: 173.5 (C), 168.8 (C), 162.2 (C), 151.8 (C), 138.5 (C), 134.9 (C), 
133.0 (CH), 128.2 (CH), 124.0 (CH), 123.2 (CH), 115.0 (CH), 114.3 (C), 
107.9 (CH), 79.9 (C), 51.8 (OCH3), 39.9 (CH2), 39.3 (CH2), 36.7 (CH2), 
34.0 (C(CH3)3), 31.1 (CH2) and 23.4 (3CH3) ppm. IR (ATR) υ: 2952 (NH), 
1795 (CO), 1748 (CO), 1717 (CO) and 1659 (CO) cm1. MS (ESI) m/z: 
445 (MH+). HRMS calcd for C23H29N2O7 (MH
+): 445.1969; found, 
445.1975. 
Quinazolinedione 40  A solution of the alkene 39 (45 mg, 0.1 mmol) in 
ethanol (1 mL) under hydrogen atmosphere was added via canula to a 
suspension of Pd-C (5 mg, 10%) in ethanol (0.5 mL) under hydrogen 
atmosphere. The resulting suspension was stirred at room temperature 
for 12 h. Hydrogen was removed under vacuo and the suspension was 
filtered through a plug of Celite. The filtrate and the washings were 
concentrated under reduced pressure. The resulting residue was purified 
by flash chromatography, eluting with (4:1) diethyl ether/ethyl acetate, to 
afford the saturated quinazolinedione 40 (38 mg, 84%) as a white foam. 
[α]D
20 = +7.3º (c1.25, CHCl3). 
1H NMR (250 MHz, CDCl3) δ: 10.20 (s, 1H, 
NH), 8.12 (dd, J = 8.0 and 1.0 Hz, 1H, ArH), 7.63 (td, J = 8.5 and 1.4 Hz, 
1H, ArH), 7.24 (t, J = 7.9 Hz, 1H, ArH), 7.13 (d, J = 8.1 Hz, 1H, ArH), 
5.16 (s, 1H, CH), 4.08 (t, J = 7.2 Hz, 2H, NCH2), 3.66 (s, 3H, OCH3), 2.82 
(s, 2H, CH2CO2), 1.86–1.71 (m, 4H, 2CH2) and 0.93 (s, 9H, 3CH3) ppm. 
13C NMR (63 MHz, CD3OD) δ: 173.6 (C), 168.5 (C), 162.0 (C), 151.6 (C), 
138.1 (C), 134.7 (CH), 128.0 (CH), 123.1 (CH), 114.6 (CH), 114.2 (C), 






107.8 (CH), 79.8 (C), 51.6 (OCH3), 40.3 (CH2), 39.2 (CH2), 33.9 (CH2), 
33.2 (C(CH3)3), 27.2 (CH2), 26.5 (CH2), 23.2 (3CH3) and 22.6 (CH2) 
ppm. IR (ATR) υ: 2952 (NH), 1790 (CO), 1743 (CO), 1711 (CO) and 
1649 (CO) cm1. MS (ESI) m/z: 447 (MH+). HRMS calcd for C22H31N2O7 
(MH+): 447.2126; found, 447.2120. 
Acid 19  A solution of the diester 40 (35 mg, 0.08 mmol) in THF (0.8 
mL) was treated with aqueous LiOH (4.8 mL, 0.48 mmol, 0.1 M) and 
stirred at room temperature for 6 h. The reaction mixture was diluted with 
ethyl acetate and MilliQ water. The organic layer was separated and the 
aqueous extract was washed with ethyl acetate (×3). The aqueous layer 
was treated with Amberlite IR-120 (H+) until pH 6. The filtrate and the 
washings were lyophilized to give the acid 19 (22 mg, 76%) as a white 
solid. [α]D
20 = –14.0º (c1.0, H2O). Mp: 177.9–178.1 ºC. 
1H NMR (500 MHz, 
D2O) δ: 8.10 (d, J = 8.0 Hz, 1H, ArH), 7.83 (td, J = 7.9 Hz and 1.3 Hz, 1H, 
ArH), 7.42  (t, J =7.7 Hz, 1H, ArH), 7.31 (t, J = 8.2, 1H, ArH), 4.07 (t, J = 
7.3 Hz, 2H, NCH2), 3.15 (d, J = 16.3 Hz, 1H, CHH), 2.86 (d, J = 16.3 Hz, 
1H, CHH), 1.94–1.81 (m, 2H, CH2), 1.75 (q, J = 7.7 Hz, 2H, CH2), 1.68–
1.56 (m, 1H, CHH), 1.48 (q, J =7.6 Hz, 2H, CH2) and 1.44–1.37 (m, 1H, 
CHH) ppm. 13C NMR (63 MHz, D2O) δ: 178.4 (C), 174.5 (C), 164.6 (C), 
152.1 (C), 138.8 (C), 136.0 (CH), 127.5 (CH), 123.9 (CH), 115.5 (CH), 
113.9 (C), 75.8 (C), 43.5 (CH2), 41.2 (CH2), 38.8 (CH2), 26.9 (CH2), 26.3 
(CH2) and 22.5 (CH2) ppm. IR (ATR) υ: 3325 (OH) and 1582 (CO) cm
1. 
MS (ESI) m/z: 363 (M–H). HRMS calcd for C17H19N2O7 (M–H): 363.1198; 
found, 363.1198. 
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A multidisciplinary approach to identify and optimize a quinazolinedione-based 
ligand that would reduce the flexibility of the substrate-covering loop (catalytic loop) 
of the type II dehydroquinase from Helicobacter pylori is presented. This enzyme is 
essential for the survival of this pathogenic bacterium and is involved in the 
biosynthesis of the aromatic amino acids. 
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